| Literature DB >> 35501398 |
Martina Poletti1,2, Agatha Treveil1,2, Luca Csabai1,3, Leila Gul1, Dezso Modos1,2, Matthew Madgwick1,2, Marton Olbei1,2, Balazs Bohar1,3, Alberto Valdeolivas4,5, Denes Turei4,5, Bram Verstockt6,7, Sergio Triana8,9, Theodore Alexandrov10,11, Julio Saez-Rodriguez4,5,11, Megan L Stanifer12, Steeve Boulant12, Tamas Korcsmaros13,14,15.
Abstract
Increasing evidence points towards the key role of the epithelium in the systemic and over-activated immune response to viral infection, including SARS-CoV-2 infection. Yet, how viral infection alters epithelial-immune cell interactions regulating inflammatory responses, is not well known. Available experimental approaches are insufficient to properly analyse this complex system, and computational predictions and targeted data integration are needed as an alternative approach. In this work, we propose an integrated computational biology framework that models how infection alters intracellular signalling of epithelial cells and how this change impacts the systemic immune response through modified interactions between epithelial cells and local immune cell populations. As a proof-of-concept, we focused on the role of intestinal and upper-airway epithelial infection. To characterise the modified epithelial-immune interactome, we integrated intra- and intercellular networks with single-cell RNA-seq data from SARS-CoV-2 infected human ileal and colonic organoids as well as from infected airway ciliated epithelial cells. This integrated methodology has proven useful to point out specific epithelial-immune interactions driving inflammation during disease response, and propose relevant molecular targets to guide focused experimental analysis.Entities:
Mesh:
Year: 2022 PMID: 35501398 PMCID: PMC9061772 DOI: 10.1038/s41540-022-00224-x
Source DB: PubMed Journal: NPJ Syst Biol Appl ISSN: 2056-7189
Fig. 1Integrated workflow to analyse the intracellular and intercellular effect of SARS-CoV-2 in the gut.
Schematic workflow illustrating the different analytical steps used to construct the intracellular and intercellular signalling networks between epithelial cells in SARS-CoV-2 infected intestinal organoids (ileal and colonic organoids, 24 h infection) or moderate COVID-19 upper airway ciliated epithelial and immune cell types.
Fig. 2Differentially expressed ligands driving upregulated and downregulated intercellular interactions between colonic and ileal infected immature enterocytes and resident immune cells upon infection in the colon and ileum.
a Heatmap showing the number of interactions between immature enterocytes and resident immune cells. Interactions driven by upregulated and downregulated ligands (ligand direction) are shown separately for infected and bystander cells (status), and for ileum and colonic organoids. The intensity of the colour indicates the number of interactions with the immune cell types whose receptor is targeted by the epithelial cells ligands. The numbers on the ligand direction row refer to the number of upregulated or downregulated ligands driving the indicated interactions with immune cells for the different groups/conditions. Abbreviations: Ileum: inf_macrophage infected macrophage, mast mast cell, CD8_Trm_cyto Resident memory cytotoxic T cell, DC2 dendritic cell 2, Trm Tissue-resident memory T cell, gd_Tcell Gamma delta (γδ) T cells, ILC Innate lymphoid cell, mem_Bcell memory B cell, naive_Bcell naive B cell, TFH_like T follicular helper cells, Trm_Th17 Tissue-resident memory Th17 cells, Treg Regulatory T cell, Tcyto Cytotoxic T cell, Tmem Memory T cells. Colon: ILC Innate lymphoid cell, CD8_IL17 IL-17+ CD8+ T cells, DC dendritic cells, GC_Bcell Germinal center B cells, CD4_PD1 mast mast cell, Treg Regulatory T cell, NK Natural Killer cell, CD4_MThi high mitochondrial CD4+ T cell, CD4_memory CD4+ Memory T cell, CD4_activ_fos_high activated CD4+ T cells (high/low c-fos), CD8_LP CD8+ lymphocyte-predominant cells, CD8_IEL CD8+ intraepithelial lymphocytes. b Venn diagrams showing the number of ligands of the infected immature enterocytes–immune cells intercellular network that are unique or shared between the ileum and colon. Upregulated and downregulated ligands are shown separately. The full list of ligands is available as Table 1.
Ligands in ligand–receptor interactions in the colon and ileum.
| Tissue | Direction | Number | Ligands |
|---|---|---|---|
| Colon only | Upregulated | 1 | FAS |
| Colon only | Downregulated | 13 | CALM3, APP, AREG, LAMB3, LRPAP1, IL32, CD47, HSP90AA1, CD55, LAMC2, HLA-E, LGALS3BP, PLAUR |
| Ileum only | Upregulated | 15 | EDN2, CXCL8, CX3CL1, CFLAR, CSF1, EDN1, TNFSF13B, TNFSF10, EFNA1, PLAU, CCL5, CXCL11, BMP2, BST2, IFNL1 |
| Ileum only | Downregulated | 8 | MDK, SPTAN1, ARPC5, FAM3C, GRN, DSC2, CALR, LYZ |
| Colon and ileum | Upregulated | 5 | CXCL2, CXCL10, ICAM1, CXCL3, TNF |
| Colon and ileum | Downregulated | 16 | PI3, SLPI, HLA-A, CDH1, CALM2, S100A6, HSP90B1, TIMP2, RTN4, ADAM9, HLA-B, HLA-C, ANXA1, CALM1, PSAP, B2M |
Table listing the number of ligands of infected immature enterocytes–immune cells intercellular network that are unique or shared between the ileum and colon.
Fig. 3Overview of intracellular and intercellular signalling of colonic and ileal infected immature enterocytes upon SARS-CoV-2 infection.
a, b Overview of intracellular and intercellular signalling upon SARS-CoV-2 infection in colonic (a) and ileal (b) infected immature enterocytes and immune cell populations. From left to right: signalling cascade going from SARS-CoV-2 molecules (proteins or miRNAs) to differentially expressed ligands on immature enterocytes and binding receptor groups on immune cells. Intracellular network: SARS-COV-2 molecules are grouped separately if they are viral proteins (bottom) or miRNAs (top). Differentially expressed ligands for which no upstream signalling was identified, but downstream intercellular connections were predicted are excluded from this figure. Differentially expressed ligands are grouped based on the direction of regulation, which is indicated with blue when downregulated (bottom) and red when upregulated (top) when comparing SARS-CoV-2 infected vs uninfected conditions. Colours of the nodes and of the functional analysis indicate if the original network was a miRNA only (yellow), viral protein only (black) or both viral protein and miRNA (grey). Functional overrepresentation analysis was carried out for the “PPI layer” of the intracellular network which includes human binding proteins, intermediary signalling proteins and TFs (adj p value < 0.05, n > 3). Intercellular network: Size of the receptor node represents the sum of receptors within the group targeted by each incoming ligand. Functional analysis is indicated for ligand–receptor groups. Receptor groups layout is based on whether they contributed to the functional analysis of upregulated interactions (red) or downregulated interactions (blue). Receptor groups not contributing to any functions are indicated in light grey.
Fig. 4Overview of upregulated and downregulated ligand–receptor interactions and participating receptors between infected immature enterocytes and resident immune cells upon infection in the colon and ileum.
a Venn diagrams showing the number of ligand–receptor interactions in the infected immature enterocytes–immune cells intercellular networks that are unique or shared between the ileum and colon. Intercellular interactions driven by upregulated and downregulated ligands are shown separately. The full list of ligand–receptor interactions is available as Table 3. b Venn diagrams showing the number of receptors in the infected immature enterocytes–immune cells intercellular networks that are unique or shared between the ileal and colonic networks. Receptors targeted by upregulated ligands and downregulated ligands are shown separately. The full list of receptors is available as Table 2.
Ligand–receptors in intercellular interactions in the colon and ileum.
| Tissue | Direction | Number | Ligand–receptor interactions |
|---|---|---|---|
| Colon only | Upregulated | 1 | FAS _ RIPK1 |
| Colon only | Downregulated | 125 | APP _ TNFRSF21, CD74, CCR5, SLC45A3, CAV1, NCSTN, FCGR2B, GPC1, LRP1, NGFR, ADRA2A |
| AREG _ LTK, CSF1R, MERTK, INSR, NTRK1/2/3, ROR1/2, PDGFRB, LMTK2, FLT3, PTK7, MET, TIE1, AATK, DDR2, MST1R, AXL, TYRO3, MUSK, RET, PDGFRA, RYK | |||
| CALM1 _ PDE1A | |||
| CALM2 _ PDE1A | |||
| CALM3 _ MYLK, GP6, KCNQ1/5, PDE1A/B/C, INSR, ESR1/2, AKT1 | |||
| CD47 _ SIRPG | |||
| CD55 _ CD97, AKT1, CR1 | |||
| HLA-C _ LILRA3 | |||
| HLA-E _ KLRC1/2/4, SLC16A4, KIR2DL3/3DL2 | |||
| HSP90AA1 _ NR3C1, CFTR, TGFBR1/2, AKT1, ITGB3, AHR, NOD2, RIPK1 | |||
| IL32 _ PTGER1, MET | |||
| LAMB3 _ CD151, COL17A1, ITGA1/2/3/4/5/6/7/8/9/10/11/V, ITGB1/3/4/5/6/7/8, AKT1, PRNP | |||
| LAMC2 _ AKT1, ITGA1/2/3/4/5/6/7/8/9/10/11/V, ITGB1/3/4/5/6/7/8, COL17A1, PRNP, CD151 | |||
| LGALS3BP _ VANGL1, ITGB1 | |||
| LRPAP1 _ LDLR, VLDLR, SORL1, SORT1, LRP1/8 | |||
| PLAUR _ ITGB3 | |||
| Ileum only | Upregulated | 219 | BMP2 _ AMHR2, SMO, ACVR2A/R2B/R1/RL1, BMPR1A/1B/2, ENG, CDH11 |
| BST2 _ LILRA4 | |||
| CFLAR _ RIPK1 | |||
| CSF1 _ PDGFRB, DDR2, LMTK2, TYRO3, RYK, MUSK, MET, CELSR3, SLC7A1, RET, ITGB3/AV, INSR, ALK, CSF1R/2RA/3R, ROR1, MSR1/T1R, NTRK1/2/3, MERTK, TIE1, AATK, AXL, ROR2, PTK7, LTK, PDGFRA, FLT3 | |||
| CCL5 _CX3CR1, CCR1/2/3/4/5/6/7/8/9, CXCR1/2/3/4/5/6/10, ACKR1/2/4, GPR75, SDC1, ADRA2A, CD4, GRM7, XCR1 | |||
| CX3CL1_CXCR1/2/3/4/5/6, CCR1/2/3/4/5/6/7/8/9/10, CX3CR1, XCR1 | |||
| CXCL10_CXCR1/2, GRM7, CCR3/6/8 | |||
| CXCL11_XCR1, CCR1/2/3/4/6/5/7/8/9/10, ACKR1, CX3CR1, CXCR1/2/3/4/5/6, ADRA2A, ACKR3 | |||
| CXCL2 _ CCR3/6/8, ACKR1, CXCR1, CXCR2, GRM7 | |||
| CXCL3 _ CCR3/6/8, CXCR1, CXCR2, GRM7 | |||
| CXCL8 _ CCR1/2/3/4/5/6/7/8/9/10, SDC1/3, CX3CR1, ITGAM, CXCR1/2/3/4/5/6, XCR1, ACKR1, CDH5/79A, LPAR2, GRM7, ADRA2A, | |||
| EDN1 _ EDNRA/B, ADGRL4, AR, MCAM, NPR3, CYSLTR1/2, AKT1, ADCY9, KEL | |||
| EDN2_EDNRA/B, KEL | |||
| EFNA1 _ RET, INSR, ROR1, NTRK1/2, PDGFRB, TYRO3, MERTK, EPHA10, MST1R, ALK, RYK, AATK, AXL, DDR2, PTK7, LMTK2, CSF1R, FLT3, PDGFRA, NTRK3, LTK, TIE1, MUSK, ROR2, MET | |||
| IFNL1 _ IFNLR1 | |||
| PLAU _ ITGA3/A5/AV/AM/B1/B5, VLDLR, MRC2, LRP1, IGF2R, ST14 | |||
| TNF _ SLC5A11, TRPV1, PTPRU | |||
| TNFSF10 _ TNFRSF10B/C/D, RIPK1 | |||
| TNFSF13B _ TNFRSF17/13B/13C | |||
| Ileum only | Downregulated | 73 | ANXA1 _ GRM7, GRIN2A |
| ARPC5 _ ADRB2, LDLR | |||
| B2M _ KIR2DL1/3DL1, AR | |||
| CALM1 _ CRHR1, SCN4A, TRPC3, GRM3/4/7, SCTR, PTH2R, KCNQ3, AQP6, MIP, GRIN2A, PLPP6, OPRM1; CALM2_PLPP6, TRPC3/V1, SCN4A, GRM7, AQP6, GRIN2A, KCNQ3 | |||
| CALR _ ITGA2B/3/V, LRP1, SCARF1, PDIA3, AR, BDKRB2 | |||
| CDH1 _ CDH2, | |||
| DSC2 _ DSG2 | |||
| FAM3C _ CLEC2D | |||
| GRN _ SORT1 | |||
| HLA-A _ KIR2DL1/2DL4/3DL3/3DL1, KLRC3 | |||
| HLA-B _ KIR3DL3, KIR3DL1, KIR2DL1, KLRC3, KIR2DL4 | |||
| HLA-C _ KIR2DL4/2DL1/3DL1/3DL3, KLRC3 | |||
| HSP90B1 _ AR | |||
| LYZ _ ITGAL | |||
| MDK _ TSPAN1, SDC1/3, GPC2, ITGA4/6, PTPRB, ITGB1, LRP1, ALK | |||
| PSAP _ AR, GPR37/37L1 | |||
| RTN4 _ RTN4RL1 | |||
| SPTAN1 _ PTPRA | |||
| Colon and ileum | Upregulated | 66 | TNF_CD83/H11, F2RL1/F3, TNFRSF21, SPHK1, NR3C1, AKT1, TRADD, RIPK1, MYLK, INSR, PPARG, PIGR, GPR160, PTPRS, CELSR2 |
| CXCL3 _ CXCR3/4/5/R1, CCR1/2/4/5/7/9/10, XCR1, ADRA2A | |||
| CXCL10 _ CX3CR1, CCR1/2/4/5/7/9/10, CXCR3/4/5/6, ADRA2A, XCR1 | |||
| CXCL2_CXCR6 / CCR9 / CCR1 / CXCR5 / XCR1 CXCR3 / CXCR4 / CCR2 / CCR5 / CX3CR1 / ADRA2A / CCR4 / CCR7 / CCR10 | |||
| ICAM1 _ ITGAX/L/M, IL2RG/RA, CDH5, CAV1 | |||
| Colon and ileum | Downregulated | 104 | ADAM9 _ ITGA3/6/V, ITGB1/5 |
| ANXA1 _ LMTK2, ADRA2A, FPR3, CCR10, DYSF | |||
| B2M _ PDIA3, KLRC1/2, KIR2DL3, LILRB2, HFE, CD247, IL2RA/RB/RG, CD1A/B, CD3G/D | |||
| CALM1 _ KCNQ1/5, PDE1B/C, MYLK, RYR1, INSR, VIPR1, GP6, PTPRA, GLP2R, KCNN4, ESR1/2 | |||
| CALM2 _ KCNQ1/5, ESR1/2, TRPC1, MYLK, RYR1, PDE1B/C, INSR, GP6 | |||
| CDH1 _ ITGAE/B7, LRP5/6, MET, KLRG1 | |||
| HLA-A _ IL2RA, KIR2DL3/3DL2, KLRC1/2/4, LILRB2, IL2RB/RG, CD3G/D, APLP2 | |||
| HLA-B _ KLRC1/2/4, CD3G/D, LILRB2, CANX, KIR2DL3/3DL2 | |||
| HLA-C _ CD3G, KIR2DL3/3DL2, CD3D, KLRC1/2/4, LILRB2 | |||
| HSP90B1 _ ASGR1, TLR1/2/4/7, LRP1 | |||
| PI3 _ PLD2 | |||
| PSAP _ CELSR1, LRP1, CD1B, SORT1 | |||
| RTN4 _ NGFR, TNFRSF19, GJB2 | |||
| S100A6 _ ESR1 | |||
| SLPI _ CD4, PLSCR1/4 | |||
| TIMP2 _ ITGA3, ITGB1 |
Table listing the number of ligand–receptor interactions in infected immature enterocytes–immune cells intercellular network that are unique or shared between the ileal and colonic networks. The direction column indicates the direction of the expression change epithelial ligand driving each intercellular interaction. Interactions are indicated as follows: ligand_receptor1, receptor2, receptor3. Receptors belonging to the same class (e.g. calmodulins) are indicated as follows: CALM1/2/3.
Receptors in ligand–receptor interactions in the colon and ileum.
| Tissue | Direction | Number | Receptors |
|---|---|---|---|
| Colon only | Upregulated | 0 | – |
| Colon only | Downregulated | 63 | ITGA1,2,7,8,910, ITGB4,6,8, NOD2, LRP8, CD151, CD74, CD97, TGFBR1,2, SLC45A3, SLC16A, SORL1, VANGL1, FCGR2B, SIRPG, PRNP, LILRA3, PDE1A, GPC1, CFTR, PTGER1, CR1, NCSTN, AHR, COL17A1 |
| Ileum only | Upregulated | 88 | MCAM, CYSLTR1/2, ACVR1/2B/L1/2 A, SLC5A11, SLC7A1, ENG, TNFRSF13B/13 C/10 C/17/10B/10D, LILRA4, CELSR3, ADGRL4, ADCY9, ACKR2/3/4, EDNRA, CCR3/6/8, CXCR1/2, EPHA10, KEL, CSF3R/2RA, EDNRB, BMPR2/R1A/R1B, SMO, AMHR2, GPR75, LPAR2, NPR3, ACKR1, IFNLR1, ST14, MRC2, CD79A, IGF2R, PTPRU, MSR1 |
| Ileum only | Downregulated | 38 | TSPAN1, SCTR, KIR2DL4, KIR3DL1, GRM3, ADRB2, PTH2R, BDKRB2, GRIN2A, KLRC3, PLPP6, CRHR1, CLEC2D, GPR37, GPR37L1, ITGA2B, SCN4A, CDH2, PTPRB, AQP6, DSG2, KIR2DL1, KIR3DL3, MIP, KCNQ3, TRPC3, GRM4, SCARF1, RTN4RL1, GPC2, OPRM1 |
| Colon and ileum | Upregulated | 38 | F2RL1, ITGAM/X, F3, CXCR3/4/5/6, CCR1/2/4/7/9, CX3CR1, XCR1, PTPRS, PIGR, GPR160, CELSR2, PPARG, CDH5, CD83, CDH11, SPHK1, TRADD |
| Colon and ileum | Downregulated | 66 | TLR1/2/4/7, VIPR1, TNFRSF19, PLD2, PLSCR1/4, SORT1, HFE, GP6, KLRC1/2/4, KLRG1, PDE1B/1 C, PDIA3, CD1A/B, CD3D/G, CD247, ITGAE, ITGA4/6, ITGB7, LILRB2, NGFR, GJB2, LRP5/6, FPR3, LDLR, RYR1, APLP2, CELSR1, KCNN4, KCNQ1/5, GLP2R, ESR1/2, CANX, IL2RB, ASGR1, KIR2DL2/3, PTPRA, DYSF, TRPC1 |
Table listing number of receptors involved ligand–receptor interactions in the infected immature enterocytes–immune cells intercellular network that are unique or shared between the ileum and colon. The direction column indicates the direction of the expression change of the epithelial ligand driving each intercellular interaction.
Fig. 5Overview of upregulated and downregulated ligands and ligand–receptor interactions between infected immature enterocytes and resident immune cells upon infection in the colon and ileum.
a, b Bar plot showing the upregulated and downregulated ligands in the colonic (a) and ileal (b) infected immature enterocytes–immune cell network scored by number of interactions (height of the bar plot) and number of immune cells targeted (black dots). Upregulated ligands are shown in red and downregulated ligands in blue.
Fig. 6Receptors involved in intercellular interactions between colonic and ileal infected immature enterocytes and resident immune cells.
a, b Bar plot showing the immune receptors targeted by upregulated (top graph) and downregulated (bottom graph) ligands in colonic (a) and ileal (b) infected immature enterocytes, scored by number of interactions (height of the bar plot) and number of immune cells targeted (black dots). The colour of the bar plots indicates the number of ligands targeting each of the receptors indicated. This plot only shows the top 25 receptors by number of interactions, and the full plot is available as Supplementary Fig. 6.
Fig. 7Ligands of infected immature enterocytes involved in the strongest up and downregulated interactions upon SARS-CoV-2 infection in the colon and ileum.
a, b Heatmap showing the upregulated and downregulated interactions in the colon (a) and ileum (b) between intestinal epithelial ligands and resident immune cells upon infection of immature enterocytes with SARS-CoV-2. The strength of the interaction is expressed by accounting for the number of interactions between epithelial ligands and immune receptors and the level of receptor expression of immune cells. The strength of the interaction, named “sum of expression values”, is visualised using a colour gradient from white (weakeast interactions) to purple (strongest interactions). Abbreviations: Ileum: inf_macrophage infected macrophage, mast mast cell, CD8_Trm_cyto Resident memory cytotoxic T cell, DC2 dendritic cell 2, Trm Tissue-resident memory T cell, gd_Tcell Gamma delta (γδ) T cells, ILC Innate lymphoid cell, mem_Bcell memory B cell, naive_Bcell naive B cell, TFH_like T follicular helper cells, Trm_Th17 Tissue-resident memory Th17 cells, Treg Regulatory T cell, Tcyto Cytotoxic T cell, Tmem Memory T cells. Colon: ILC Innate lymphoid cell, CD8_IL17 IL-17+ CD8+ T cells, DC dendritic cells, GC_Bcell Germinal center B cells, CD4_PD1 mast mast cell, Treg Regulatory T cell, NK Natural Killer cell, CD4_MThi high mitochondrial CD4+ T cell, CD4_memory CD4+ Memory T cell, CD4_activ_fos_high activated CD4+ T cells (high/low c-fos), CD8_LP CD8+ lymphocyte-predominant cells, CD8_IEL CD8+ intraepithelial lymphocytes.
Fig. 8Receptors on immune cell types involved in the strongest up and downregulated interactions upon SARS-CoV-2 infection in the colon and ileum.
a, b Heatmap showing the upregulated and downregulated interactions in the colon (a) and ileum (b) between receptors and resident immune cell types upon infection of immature enterocytes with SARS-CoV-2. The number of interactions in which each receiving receptor on immune cell types is involved is visualised using a colour gradient from blue (weakest interactions) to red (strongest interactions). Abbreviations: Ileum: inf_macrophage infected macrophage, mast mast cell, CD8_Trm_cyto Resident memory cytotoxic T cell, DC2 dendritic cell 2, Trm Tissue-resident memory T cell, gd_Tcell Gamma delta (γδ) T cells, ILC Innate lymphoid cell, mem_Bcell memory B cell, naive_Bcell naive B cell, TFH_like T follicular helper cells, Trm_Th17 Tissue-resident memory Th17 cells, Treg Regulatory T cell, Tcyto Cytotoxic T cell, Tmem Memory T cells. Colon: ILC Innate lymphoid cell, CD8_IL17 IL-17+ CD8+ T cells, DC dendritic cells, GC_Bcell Germinal center B cells, CD4_PD1 mast mast cell, Treg Regulatory T cell, NK Natural Killer cell, CD4_MThi high mitochondrial CD4+ T cell, CD4_memory CD4+ Memory T cell, CD4_activ_fos_high activated CD4+ T cells (high/low c-fos), CD8_LP CD8+ lymphocyte-predominant cells, CD8_IEL CD8+ intraepithelial lymphocytes.
Fig. 9Overview of intracellular and intercellular signalling upon SARS-CoV-2 infection of colonic and ileal immature enterocytes and resident immune cells.
SARS-CoV-2 directly infects colonic and ileal immature enterocytes. Upon infection, transcription factors ATF2/3, JUN, FOS, STAT1 and NFKB1 are modulated, resulting in altered intracellular signalling pathways and altered ligands expression, including upregulation of chemokines (CXCLs) and human leukocyte antigens (HLAs), and downregulation of laminins (LAMB/Cs). Altered ligands expression drives differential intercellular interactions between epithelial ligands and immune cell receptors (chemokine receptors (CXCRs), killer cell lectin-like receptors (KLRs) and integrins (ITGs)) expressed on immune cells.
Key differentially expressed ligands produced by infected immature enterocytes drive the inflammatory process upon SARS-CoV-2 infection.
| Ranking | Ligand | Ligand description | Organoid type | Expression change upon SARS-CoV-2 infection | Regulation by cytokines | Known to affect immune cells | Directly explain patients’ blood cytokine levels |
|---|---|---|---|---|---|---|---|
| 1 | CXCL2 | C-X-C Motif Chemokine Ligand 2 | Colonic, Ileal | Up | IFNG, TNF, IL-17, IL-22 (up) | Neutrophils (1,2), fibroblasts, T cells, NK cell and CD8a+ DCs (1), leukocytes (2) | ✓ |
| 1 | CXCL3 | C-X-C Motif Chemokine Ligand 3 | Colonic, Ileal | Up | TNF, IL-22 (up) | Neutrophils, fibroblasts (1), T cells (2) | ✓ |
| 1 | CXCL10 | C-X-C Motif Chemokine Ligand 10 | Colonic, Ileal | Up | IFNG, TNF (up) | DC, Th1, NK cells, B cells, monocytes (1), and 29 additional immune cell types (2) | ✓ |
| 1 | CSF1 | Colony stimulating factor 1 | Colonic | Up | 35 immune cell types (2) | ✓ | |
| 1 | CXCL11 | C-X-C Motif Chemokine Ligand 11 | Ileal | Up | n.d. (3) | DC (1,2), B cells, NK cells, Th1, monocytes, macrophages (1), lymphocytes, T cells, CD8+ alpha/beta T cell (2) | ✓ |
| 2 | TNFSF13B | TNF Superfamily Member 13b | Ileal | Up | n.d. | B cell, T cell, follicular B cell, naïve B cell, Th17, neutrophils, monocytes (2) | ✓ |
| 2 | LAMC2 | Laminin Subunit Gamma 2 | Colonic | Down | TNF, IL-22 (up) | ||
| 2 | CCL5 | C-C Motif Chemokine Ligand 5 | Ileal | Up | n.d. (3) | T cells, basophils, eosinophils, macrophages, monocytes, NK cells, DC, Memory T cells, Th1 and Th2 (1), and 23 additional immune cell types (2) | |
| 2 | CX3CL1 | C-X3-C Motif Chemokine Ligand 1 | Ileal | Up | n.d. (3) | Monocytes, T cells, neutrophil, NK, DC, Mast cells and microglia (1), and 19 additional immune cell types (2) | |
| 2 | CXCL8 | C-X-C Motif Chemokine Ligand 8 | Ileal | Up | n.d. (3) | Neutrophils, macrophages, basophils, naïve T cells, CD8+ T cells, monocytes (1), and 44 additional immune cell types (2) | |
| 3 | ICAM1 | Intercellular Adhesion Molecule 1 | Colonic, Ileal | Up | IFNG, TNF, IL-22 (up) | ||
| 3 | IL32 | Interleukin 32 | Colonic | Down | IFNG, TNF (up) | ||
| 3 | AREG | Amphiregulin | Colonic | Down | IFNG (up), IL-13 (down) | ||
| 3 | TNF | Tumour Necrosis Factor | Colonic, Ileal | Up | TNF, IL-22 (+) | Non-specific: 129 immune cell types (2) | |
| 3 | B2M | Beta-2-immunoglobulin | Colonic, Ileal | Down | IFNG (up) | ||
| 3 | HLA-A | Major Histocompatibility Complex, Class I, A | Colonic, Ileal | Down | IFNG (up) | ||
| 3 | HLA-B | Major histocompatibility complex, class I, B | Colonic, Ileal | Down | IFNG (up) | ||
| 3 | LAMB3 | Laminin Subunit Beta 3 | Colonic | Down |
Table showing a list of top-ranked differentially expressed ligands in infected immature enterocytes which were identified to drive inflammation upon SARS-CoV-2 infection. The ranking of the ligands was performed using multiple criteria as explained in the Methods. ‘Organoid type’ indicates whether the expression change of the ligand was found in ileal or colonic infected immature enterocytes upon SARS-CoV-2 infection, respectively. ‘Expression change upon SARS-CoV-2 infection’ indicates the direction of expression change of the ligand in infected immature enterocytes upon SARS-CoV-2 infection. ‘Regulation by cytokines’ indicates whether ligand expression was found to be regulated by cytokines during inflammation based on results from[40]. Ileal data was not available (n.d.) in this study, so no conclusion could be drawn for ileal ligands. ‘Known to affect immune cells’ indicates whether the ligand was found to be regulated by immune cells using data from ImmunoGlobe[41] and ImmuneXpresso[42] databases. ‘Directly explain patient blood cytokine levels’ indicates whether the ligand was found to directly regulate blood cytokine levels in COVID-19 patients from[5].